B-1722 Bosutinib Isomer 1, Free Base, >99%

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 33 mg/mL; soluble in ethanol at 10 mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is etimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

BWC-102 BWC-101

View the SDS for this product

• This compound, our Cat. No. B-1722, which we now sell under the name Bosutinib Isomer 1, is an incorrect isomer of bosutinib.   Please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html for extensive additional information about this problem.
• X-ray, NMR and melting point data that our firm has obtained indicate that the following 17 vendors have erroneously sold this compound to one or more normal customers in the biochemical reagent marketplace, under the name "bosutinib":
  
                                                          AK Scientific                                 Eton Bioscience                                                     Selleck Chemicals                          
                                                          Alfa Aesar                                     LC Laboratories (part of PKC Pharma)                 Symansis NZ Ltd                                                                
                                                          Axon Medchem                             LKT Laboratories                                                  Synkinase                                                                                         
                                                          B-Bridge International                   Medchem Express                                                Wuhan Sunrise                                                                      
                                                          Biorbyt Ltd                                    Reliable ChemTech                                               Xingcheng Chempharm
                                                          Biovision Inc.                                Santa Cruz Biotechnology    
  
  
  
• An 18th vendor has also erroneously sold an incorrect isomer of bosutinib. Published information and private communications we have received from Prof. Stefan Knapp's laboratory indicate that an 18th vendor, "Company A", also provided an incorrect isomer of bosutinib to the biochemical research reagents marketplace, specifically to the Knapp laboratory and perhaps to other laboratories. The Knapp group used the material from Company A in an X-ray crystallography study proving that the compound from Company A was not the correct bosutinib isomer.
• This X-ray study clearly distinguishes Company A's product from correct bosutinib, but the data obtained apparently could not conclusively establish the structure of the incorrect compound.
• Contrary to an erroneous report in Chemical and Engineering News, Company A is not Calbiochem, the latter having issued a public statement on this topic http://www.millipore.com/antibodies/flx4/bosutinib_inhibitor_announcement.
• We have not yet received permission from the Knapp laboratory to release the name of Company A. NOTE: The erroneous compound that the 17 vendors listed above all sold is the compound described on this page, namely "Bosutinib Isomer 1", Cat. No. B-1722, for which we have unambiguously proven the structure by X-ray crystallography.
• LC Labs XP/XR™ — X-ray Proven/X-ray Referenced Structure™. The chemical structure of our Bosutinib Isomer 1 has been unambiguously proven by single-crystal X-ray crytallography.
• We now sell the correct bosutinib isomer under our Cat. No. B-1788, "Bosutinib, Free Base".
• Unpublished kinase assay data obtained by our parent company, PKC Pharmaceuticals, Inc., indicate that bosutinib and this incorrect isomer have significantly different kinase inhibitory properties (manuscript in preparation).